Articles from Kardigan

Kardigan™, a clinical-stage precision therapeutics company developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist, today announced results from KARDINAL, a Phase 2 clinical trial evaluating the effects of tonlamarsen in patients with uncontrolled hypertension despite treatment with two or more antihypertensive medications. Data were presented at the American College of Cardiology’s Annual Scientific Session & Expo (ACC.26) and simultaneously published in The Journal of the American College of Cardiology (JACC). In the clinical trial, tonlamarsen, an investigational antisense oligonucleotide (ASO) targeting angiotensinogen (AGT), demonstrated a statistically significant reduction in plasma AGT levels and a clinically meaningful reduction in in-office systolic blood pressure (oSBP) from baseline to Week 20. These results highlight the intended biological effect of tonlamarsen and support evaluation in Kardigan’s planned Phase 2b clinical trial in patients with acute severe hypertension (ASH) post-hospitalization.

Kardigan™, a heart health company modernizing cardiovascular (CV) drug development, announced today that it will have multiple presentations at the American College of Cardiology’s Annual Scientific Session & Expo (ACC.26), taking place on March 28-30, 2026 in New Orleans. Presentations will highlight research from all three of Kardigan’s CV programs, including late-breaking data from the company’s Phase 2 KARDINAL study of tonlamarsen in patients with uncontrolled hypertension.

Kardigan™, a heart health company modernizing cardiovascular (CV) drug development, today announced its upcoming corporate presentation at the 2026 J.P. Morgan Healthcare Conference (“JPM 2026”) on Monday, January 12 at 8:00 a.m. PT. The presentation marks an important milestone for Kardigan as it enters 2026 with multiple clinical data readouts expected across its late-stage portfolio of personalized CV medicines in specific types of dilated cardiomyopathy (DCM), hypertension, and calcific aortic valve stenosis (CAVS).

Kardigan, a heart health company modernizing cardiovascular drug development, announced positive Phase 2 data on ataciguat in patients with moderate calcific aortic valve stenosis, presented today in an oral session at the American Heart Association Scientific Sessions 2025. Results demonstrated that treatment with ataciguat, an investigational oral soluble guanylate cyclase activator, slowed the progression of aortic valve calcium (AVC), leading to improvements in measures of valvular compliance, cardiac output (CO), and cardiac function when compared to placebo.

Kardigan, a heart health company modernizing cardiovascular drug development, announced today the closing of a $254 million Series B financing with participation from new investors including Fidelity Management & Research Company and accounts advised by T. Rowe Price Investment Management, Inc., and renewed support from ARCH Venture Partners and Sequoia Heritage. The company will use funds from the Series B raise to advance its pipeline of complementary candidates to target the underlying drivers of specific types of dilated cardiomyopathy (DCM), calcific aortic valve stenosis (CAVS), and acute severe hypertension (ASH).

Kardigan, a heart health company modernizing cardiovascular drug development, today announced positive Phase 2a clinical trial data evaluating danicamtiv in patients with genetic dilated cardiomyopathy (DCM). These results, presented in a late-breaking oral session at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2025 and simultaneously published in The Journal of the American College of Cardiology (JACC), demonstrated danicamtiv treatment was associated with statistically significant improvements in left atrial function index and left ventricular ejection fraction in patients with genetic DCM driven by sarcomeric mutations.

Kardigan, a heart health company modernizing cardiovascular drug development, today introduced the three late-stage clinical programs leading its robust pipeline, each strategically chosen to advance the Company’s mission of delivering multiple important medicines at a pace not previously seen in cardiology. These programs target the underlying drivers of specific types of dilated cardiomyopathy (DCM), acute severe hypertension (ASH) and calcific aortic valve stenosis (CAVS), where no treatments exist.

Kardigan, a heart health company modernizing cardiovascular (CV) drug development, announced today that it has acquired Prolaio, a clinical intelligence company advancing cardiology research and care with real-world patient data and insights. In addition to its FDA-cleared patient monitoring software, Prolaio has assembled one of the largest curated CV clinical data sets in the industry and developed world-leading analytics with an aim to predict and help clinicians proactively treat heart-related health challenges.

Kardigan, a heart health company modernizing cardiovascular drug development, launched today with a mission to develop multiple targeted treatments in parallel, bringing people with cardiovascular diseases closer to the cures they deserve.